Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tagamet HB generates U.S. sales of $92 mil. for SmithKline in 1997.

This article was originally published in The Tan Sheet

Executive Summary

SMITHKLINE BEECHAM TAGAMET HB U.S. SALES TOTAL $92 MIL. IN 1997 and the company is "quite pleased" with the results but also acknowledges "we are not going to grow the share" in the U.S. in relation to J&J/Merck's Pepcid AC and other OTC H2 antagonists, SmithKline Beecham CEO Jan Leschly told securities analysts during a Feb. 17 teleconference from London. "We invested a lot of money up front" with Tagamet HB," he noted, "and that is now paying off, and we have a nice business" with the OTC cimetidine product, Leschly said. "We are making money on Tagamet, and it will be a nice...cash cow for us in years to come," he predicted.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088136

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel